Albuminuria in Type 2 Diabetes and Risk of Cardiorenal Outcomes
The prevalence of patients with T2D and albuminuria was 40% and may benefit from cardiovascular and renoprotective drugs, whereas 60% with normoalbuminuria still have a high residual risk of cardiovascular disease, warranting increased focus.
Authors
- Nicholas Carlson (ORCID: https://orcid.org/0000-0002-4374-470X)
- Morten Malmborg (ORCID: https://orcid.org/0000-0002-9867-3283)
- Talip E Eroglu (ORCID: https://orcid.org/0000-0002-4381-0068)
- Camilla Fuchs Andersen (ORCID: https://orcid.org/0000-0003-3151-5499)
- Deewa Zahir (ORCID: https://orcid.org/0000-0001-9564-6231)
- Lars Køber (ORCID: https://orcid.org/0000-0002-6635-1466)
- Gunnar Gislason (ORCID: https://orcid.org/0000-0002-0548-402X)
- Anojhaan Arulmurugananthavadivel (ORCID: https://orcid.org/0000-0003-2903-1700)
- Saaima Parveen (ORCID: https://orcid.org/0000-0002-8639-0817)
- Emil Loldrup Fosbøl (ORCID: https://orcid.org/0000-0002-2048-4167)
- Morten Schou (ORCID: https://orcid.org/0000-0002-1274-5072)
- Mariam Elmegaard
- J. Steen Jensen (ORCID: https://orcid.org/0000-0003-2821-9947)
- Charlotte Andersson
Institutions
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- Heart Foundation (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102254
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00